Nephrogenic systemic fibrosis

Current Opinion in Rheumatology

Volumn 22, Issue 1, 2010, Pages 54-58

  Bardin, Thomas ^a   Richette, Pascal ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Gadolinium; Magnetic resonance imaging; Nephrogenic systemic fibrosis; Renal failure

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; GADODIAMIDE; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOVERSETAMIDE; GROWTH FACTOR; IMATINIB; IRON; LANTHANUM CARBONATE; PSORALEN; RETINOID; SODIUM THIOSULFATE;

CYTOKINE RELEASE; DRUG EFFECT; DRUG EXPOSURE; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; CONTRAST MEDIA; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GADOLINIUM; HUMANS; IATROGENIC DISEASE; MAGNETIC RESONANCE ANGIOGRAPHY; MONOCYTES; NEPHROGENIC FIBROSING DERMOPATHY; RATS;

EID: 73649131663     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328333bf3d     Document Type: Review

References (48)

1. Bardin T, Richette P. Rheumatic manifestations of renal disease. Curr Opin Rheumatol 2009; 21:55-61.
2. Altun E, Semelka RC, Cakit C. Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol 2009; 16:897-905.
3. Dawson P. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies. J Magn Reson Imaging 2008; 28:797-804.
4. Gossner J. Is nephrogenic systemic fibrosis linked to the introduction of contrast-enhanced MR angiography? Radiology 2009; 251:612-613; author reply 613.
5. Graziani G, Montanelli A, Brambilla S, Balzarini L. Nephrogenic systemic fibrosis an unsolved riddle. J Nephrol 2009; 22:203-207.
6. Juluru K, Vogel-Claussen J, Macura KJ, et al. MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. Radiographics 2009; 29:9-22.
7. Kay J. Nephrogenic systemic fibrosis: A gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis 2008; 67 (Suppl 3):iii66-iii69.
8. Kribben A, Witzke O, Hillen U, et al. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol 2009; 53:1621-1628.
9. Morcos SK, Thomsen HS. Nephrogenic systemic fibrosis: more questions and some answers. Nephron Clin Pract 2008; 110:c24-31; discussion c32.
10. Nainani N, Panesar M. Nephrogenic systemic fibrosis. Am J Nephrol 2009; 29:1-9.
11. Penfield JG. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol 2008; 23:2121-2129.
12. Provenzale JM. Nephrogenic systemic fibrosis: some considerations on the debate regarding its cause. Am J Roentgenol 2008; 191:1867-1869.
13. Rodriguez Jornet A, Andreu Navarro F, Orellana Fernandez R, et al. Gadolinium- induced systematic fibrosis in advanced kidney failure. Nefrologia 2009; 29:358-363.
14. Padilla-Thornton A, Zand KR, Barrett B, et al. Canadian Association of Radiologists national advisory on gadolinium administration and nephrogenic systemic fibrosis. Can Assoc Radiol J 2008; 59:237-240.
15. ten Dam MA, Wetzels JF. Toxicity of contrast media: An update. Neth J Med 2008; 66:416-422.
16. Introcaso CE, Elenitsas R, Xu X, James WD. Periocular papules in nephrogenic systemic fibrosis. J Am Acad Dermatol 2008; 59:536-537.
17. Weigle JP, Broome DR. Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. Skeletal Radiol 2008; 37:457-464.
18. Su HS, Nazarian RM, Scott JA. Case report. Appearance of nephrogenic fibrosing dermopathy on a bone scan. Br J Radiol 2009; 82:e35-e36.
19. Deng A, Bilu Martin D, Spillane A, et al. Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: A disorder of aberrant dermal remodeling. J Cutan Pathol 2009. doi:10.1111/j.1600-0560.2009. 01301.
20. Bangsgaard N, Marckmann P, Rossen K, Skov L. Nephrogenic systemic fibrosis: late skin manifestations. Arch Dermatol 2009; 145:183-187.
21. Swaminathan S, High WA, Ranville J, et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 2008; 73:1413-1418.
22. Grobner T. Gadolinium: A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104-1108.
23. Chrysochou C, Buckley DL, Dark P, et al. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging 2009; 29:887-894.
24. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 2009; 4:461-469.
25. Bhave G, Lewis JB, Chang SS. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol 2008; 180:830-835; discussion 835.
26. Khurana A, Greene JF Jr, High WA. Quantification of gadolinium in nephrogenic systemic fibrosis: Re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol 2008; 59:218-224.
27. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 2009; 44:226-233.
28. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: A possible role for gadoliniumbased contrast media. Invest Radiol 2008; 43:65-75.
29. Steger-Hartmann T, Raschke M, Riefke B, et al. The involvement of proinflammatory cytokines in nephrogenic systemic fibrosis: A mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 2009. doi:10.1016/j.etp.2008.11.004.
30. Wermuth PJ, DelGaldo F, Jimenez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009; 60:1508-1518.
31. Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 2009; 44:74-81.
32. Perez-Rodriguez J, Lai S, Ehst BD, et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment: Report of 33 cases. Radiology 2009; 250:371-377.
33. Lu CF, Hsiao CH, Tjiu JW. Nephrogenic systemic fibrosis developed after recovery from acute renal failure: gadolinium as a possible aetiological factor. J Eur Acad Dermatol Venereol 2009; 23:339-340.
34. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008; 248:807-816.
35. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007; 56:3433-3441.
36. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008; 43:141-144.
37. Janus N, Launay-Vacher V, Karie S, et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: Results of the FINEST study. Eur J Radiol 2009. doi:10.1016/j.ejrad.2008.11.021.
38. Weinreb JC, Kuo PH. Nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am 2009; 17:159-167.
39. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008; 248:799-806.
40. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 2008; 66:175-179.
41. Ortega LM, Contreras G, Lenz O. Nephrogenic fibrosing dermopathy or nephrogenic systemic fibrosis? What do we know and what do we have to learn? Nefrologia 2009; 29:109-117.
42. Kay J. Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med 2008; 75:112; 114, 117.
43. Grebe SO, Borrmann M, Altenburg A, et al. Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposure. Clin Exp Nephrol 2008; 12:403-406.
44. Kreuter A, Gambichler T, Weiner SM, Schieren G. Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis. Arch Dermatol 2008; 144:1527-1529.
45. Duffy KL, Green L, Harris R, Powell D. Treatment of nephrogenic systemic fibrosis with Re-PUVA. J Am Acad Dermatol 2008; 59:S39-S40.
46. Kadiyala D, Roer DA, Perazella MA. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. Am J Kidney Dis 2009; 53:133-137.
47. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008; 58:2543-2548.
48. Chandran S, Petersen J, Jacobs C, et al. Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 2009; 53:129-132.